Transcode Therapeutics, Inc. — Investor Relations & Filings

Transcode Therapeutics, Inc. is a clinical-stage oncology company developing RNA-based therapeutics for metastatic cancer. The company's strategy focuses on the specific eradication of metastatic tumor cells by targeting microRNA-10b (miRNA-10b), identified as a master regulator of metastasis. Its lead therapeutic candidate, TTX-MC138, is an oligonucleotide designed to inhibit miRNA-10b. Transcode utilizes a proprietary iron oxide nanoparticle delivery platform, TTX, to transport its therapeutic candidates to tumor sites. Pre-clinical studies in murine models have demonstrated that TTX-MC138 can induce regression of established metastases in breast and pancreatic cancers. The company's approach has potential applicability across numerous cancer types where miRNA-10b is involved, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas.